Health-related quality of life in patients with solid cancer treated with immune checkpoint inhibitors: the ARON-MOUSEION-18 systematic review and meta-analysis

BACKGROUND: Health-related quality of life (HRQoL) contributes to the value of immune checkpoint inhibitors (ICIs), but assessment and reporting remain heterogeneous. METHODS: This PRISMA 2020-compliant systematic review and meta-analysis was registered in PROSPERO (CRD420261330878). PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched for RCTs of adults with solid tumors comparing ICI-based regimens with non-ICI controls and reporting global HRQoL with the EORTC QLQ-C30 GHS/QoL scale or EQ-5D-3L/5L visual analogue scale (VAS). Pooling required a visit-specific adjusted between-group estimate with a 95% confidence interval (CI) or standard error. Random-effects models (restricted maximum likelihood, Hartung-Knapp adjustment) were used. Clinical relevance was assessed using instrument-specific MID benchmarks. RESULTS: Eighty-two RCTs were included: 42 in the quantitative and 40 in the narrative synthesis, 40 reported EORTC QLQ-C30 GHS/QoL, 10 EQ-5D-3L VAS, and 14 EQ-5D-5L VAS. All pooled trials evaluated anti-PD-1-based regimens. The pooled LSMD for EORTC QLQ-C30 GHS/QoL was 1.78 points (95% CI 0.71-2.86; p = 0.002; I2 =71.9%). Neither EQ-5D VAS differ significantly. Most trial-level estimates were below the MID, and no trial showed clinically meaningful deterioration. Favorable estimates were concentrated in open-label active-control, advanced/metastatic and lung cancer trials. CONCLUSION: Anti-PD-1-based therapy results in no clinically important difference in global HRQoL compared with non-ICI controls: the small average advantage is below the MID and concentrated in open-label active-control trials. Interpretation is shaped by trial design, comparator, setting, assessment timing, and incomplete PRO reporting. Standardized PRO reporting is needed across cancer settings and ICI classes.

Authors

Institutions

Publication Details

Journal
JNCI Journal of the National Cancer Institute
Published
2026-11-17
DOI
https://doi.org/10.1093/jnci/djag431
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Health-related quality of life in patients with solid cancer treated with immune checkpoint inhibitors: the ARON-MOUSEION-18 systematic review and meta-analysis

Francesco Ciccimarra, Gerardo Cazzato, Matteo Santoni, Mohadeseh Motamed‐Jahromi et al.
JNCI Journal of the National Cancer Institute
Cancer Immunotherapy and Biomarkers
article

Health-related quality of life in patients with solid cancer treated with immune checkpoint inhibitors: the ARON-MOUSEION-18 systematic review and meta-analysis

Francesco Ciccimarra, Gerardo Cazzato, Matteo Santoni, Mohadeseh Motamed‐Jahromi, Pastore Vito, Lorenza Maistrello, Enes Erul, Francesco Massari, Elsa Vitale, Brigida Anna Maiorano, Anna Albano, Alessandro Rizzo, Oronzo Brunetti, Patrizia Nardulli, Chiara Paciolla
article en

Abstract

BACKGROUND: Health-related quality of life (HRQoL) contributes to the value of immune checkpoint inhibitors (ICIs), but assessment and reporting remain heterogeneous. METHODS: This PRISMA 2020-compliant systematic review and meta-analysis was registered in PROSPERO (CRD420261330878). PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched for RCTs of adults with solid tumors comparing ICI-based regimens with non-ICI controls and reporting global HRQoL with the EORTC QLQ-C30 GHS/QoL scale or EQ-5D-3L/5L visual analogue scale (VAS). Pooling required a visit-specific adjusted between-group estimate with a 95% confidence interval (CI) or standard error. Random-effects models (restricted maximum likelihood, Hartung-Knapp adjustment) were used. Clinical relevance was assessed using instrument-specific MID benchmarks. RESULTS: Eighty-two RCTs were included: 42 in the quantitative and 40 in the narrative synthesis, 40 reported EORTC QLQ-C30 GHS/QoL, 10 EQ-5D-3L VAS, and 14 EQ-5D-5L VAS. All pooled trials evaluated anti-PD-1-based regimens. The pooled LSMD for EORTC QLQ-C30 GHS/QoL was 1.78 points (95% CI 0.71-2.86; p = 0.002; I2 =71.9%). Neither EQ-5D VAS differ significantly. Most trial-level estimates were below the MID, and no trial showed clinically meaningful deterioration. Favorable estimates were concentrated in open-label active-control, advanced/metastatic and lung cancer trials. CONCLUSION: Anti-PD-1-based therapy results in no clinically important difference in global HRQoL compared with non-ICI controls: the small average advantage is below the MID and concentrated in open-label active-control trials. Interpretation is shaped by trial design, comparator, setting, assessment timing, and incomplete PRO reporting. Standardized PRO reporting is needed across cancer settings and ICI classes.

JNCI Journal of the National Cancer Institute
Ankara University (TR), Vita-Salute San Raffaele University (IT), Azienda USL di Bologna (IT), IRCCS San Camillo Hospital (IT), Istituto Tumori Bari (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fasa University of Medical Sciences (IR), Ospedale di Macerata (IT), University of Macerata (IT), University of Bari Aldo Moro (IT), University of Bologna (IT)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon